Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech

Author's Avatar
Feb 05, 2019
Article's Main Image

-- Xencor Receives $120 Million Upfront Payment, up to $180 Million in Development Milestones Per Program and Profit Share from Commercialized Medicines

PR Newswire